Ken Griffin Rubius Therapeutics, Inc. Transaction History

Citadel Advisors LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.14 - $0.31 $1,324 - $2,931	-9,458 Reduced 6.67%	132,322 $23,000
Q3 2022 Nov 14, 2022	SELL	$0.46 - $1.29 $97,073 - $272,228	-211,030 Reduced 59.81%	141,780 $62,000
Q2 2022 Aug 15, 2022	BUY	$0.79 - $5.98 $50,781 - $384,400	64,281 Added 22.28%	352,810 $300,000
Q1 2022 May 16, 2022	BUY	$4.25 - $10.4 $967,665 - $2.37 Million	227,686 Added 374.22%	288,529 $1.59 Million
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $404,565 - $741,425	41,794 Added 219.4%	60,843 $588,000
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $335,262 - $493,559	19,049 New	19,049 $341,000
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $569,059 - $2.27 Million	-70,955 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $52,172 - $107,675	-12,334 Reduced 14.81%	70,955 $539,000
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $230,579 - $309,918	49,587 Added 147.13%	83,289 $417,000
Q2 2020 Aug 14, 2020	SELL	$4.01 - $6.88 $427,871 - $734,102	-106,701 Reduced 76.0%	33,702 $202,000
Q1 2020 May 15, 2020	SELL	$3.74 - $9.84 $196,207 - $516,226	-52,462 Reduced 27.2%	140,403 $625,000
Q4 2019 Feb 14, 2020	SELL	$7.23 - $14.12 $532,099 - $1.04 Million	-73,596 Reduced 27.62%	192,865 $1.83 Million
Q3 2019 Nov 14, 2019	BUY	$7.85 - $15.75 $404,259 - $811,093	51,498 Added 23.96%	266,461 $2.09 Million
Q2 2019 Aug 14, 2019	BUY	$13.5 - $19.94 $2.9 Million - $4.29 Million	214,963 New	214,963 $3.38 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.